New discoveries in lung cancer research, such as the research funded by LCFA, are resulting in new treatments for lung cancer patients

How LCFA uses your donation wisely to fight lung cancer:

You Make A Donation to LCFA
Your dollars are added to contributions from other donors

We maximize your donation by adding it to dollars from LCFA’s strategic funding partners.

This leveraged donation allows LCFA to award a generous grant to a top young lung cancer investigator for 2 years of focused and intense research.

The lung cancer investigator
can now start the critical two-year process of research and discovery

Now, armed with this new evidence, the lung cancer investigator presents their findings to organizations like the National Institutes of Health (NIH) for consideration for vital next-stage grants.

Each painstaking step brings us closer to understanding how lung cancer works, how to detect it earlier, how to fight it better, and – someday – how to cure it.

Latest In Research


Dr. Garon on Immunotherapy as Salvage Treatment for Advanced Lung Cancer

from OncLive Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses the possibility of administering PD-1 or PD-L1 blockades as a third-line or salvage therapy for patients with a…


Liquid Biopsies: A Lung Cancer Game-Changer?

In early 2016, Matthew Tobin came down with a headache and persistent cough that lasted for months. When his doctor ordered an X-ray to test for pneumonia, it revealed a spot on his lung. After a tissue biopsy, doctors gave him the devastat…


Active Therapeutic Thoracic Trials – November 2017

The Ohio State University Cancer Research Center was established in 1973 and received National Cancer Institute designation in April 1976 as a comprehensive cancer center (OSUCCC). The patient care arm of the OSUCCC is the Arthur G. James C…


Tumor Mutation Burden Shows Promise as a Response Biomarker in Small Cell Lung Cancer

Tumor Mutation Burden Shows Promise in Small Cell Lung Cancer From The ASCO Post: Patients with small cell lung cancer (SCLC) and a high tumor mutation burden had a near doubling in response rate and 1-year overall survival when ipilimuma…


LCFA trio contribute to ‘cancer interception’ project

From EurekAlert: Developing diagnostic tools to "intercept" lung cancer at its earliest stage is the goal of a research team led by Boston University School of Medicine (BUSM), along with colleagues at the University of California, Los Angel…

Read More